Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000818
Abstract: Checkpoint immunotherapies (CPIs) have improved outcomes for metastatic melanoma patients, with objective response rates to combination ipilimumab and nivolumab of ~58%. Preclinical data suggest that histone deacetylase (HDAC) inhibition enhances antitumor immune activity and may… read more here.
Keywords: melanoma; inhibitor mocetinostat; mocetinostat; ipilimumab nivolumab ... See more keywords